$LRMR
Larimar Therapeutics, Inc.

2022 Q4 Form 10-Q Financial Statement

#000095017022024223 Filed on November 10, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.221M $2.931M
YoY Change 15.28% 8.48%
% of Gross Profit
Research & Development $7.218M $5.582M
YoY Change 14.72% -60.21%
% of Gross Profit
Depreciation & Amortization $78.00K $77.00K
YoY Change -11.36% -23.0%
% of Gross Profit
Operating Expenses $10.44M $8.513M
YoY Change 14.89% -49.12%
Operating Profit -$8.513M
YoY Change -49.12%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $1.014M $193.0K
YoY Change -2212.5% -357.33%
Pretax Income -$9.425M -$8.320M
YoY Change 3.19% -50.49%
Income Tax
% Of Pretax Income
Net Earnings -$9.425M -$8.320M
YoY Change 3.19% -50.49%
Net Earnings / Revenue
Basic Earnings Per Share -$0.37
Diluted Earnings Per Share -$0.21 -$0.37
COMMON SHARES
Basic Shares Outstanding 43.27M 17.71M
Diluted Shares Outstanding 22.23M

Balance Sheet

Concept 2022 Q4 2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $118.4M $124.7M
YoY Change 68.95% 59.82%
Cash & Equivalents $26.83M $86.05M
Short-Term Investments $91.60M $38.65M
Other Short-Term Assets $2.311M $2.314M
YoY Change 21.7% -23.12%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $120.7M $127.1M
YoY Change 67.22% 56.46%
LONG-TERM ASSETS
Property, Plant & Equipment $831.0K $909.0K
YoY Change -20.78% -19.91%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $638.0K $643.0K
YoY Change -4.63% -4.17%
Total Long-Term Assets $5.666M $5.888M
YoY Change -12.33% -11.92%
TOTAL ASSETS
Total Short-Term Assets $120.7M $127.1M
Total Long-Term Assets $5.666M $5.888M
Total Assets $126.4M $133.0M
YoY Change 60.68% 51.26%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.686M $849.0K
YoY Change 1.57% -51.93%
Accrued Expenses $8.408M $7.939M
YoY Change 27.55% -0.34%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $10.71M $9.420M
YoY Change 21.02% -8.6%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $4.797M $4.933M
YoY Change -11.3% -11.36%
Total Long-Term Liabilities $4.797M $4.933M
YoY Change -11.3% -11.36%
TOTAL LIABILITIES
Total Short-Term Liabilities $10.71M $9.420M
Total Long-Term Liabilities $4.797M $4.933M
Total Liabilities $15.50M $14.35M
YoY Change 8.76% -9.56%
SHAREHOLDERS EQUITY
Retained Earnings -$151.6M -$142.2M
YoY Change 30.41% 32.77%
Common Stock $262.5M $260.9M
YoY Change 45.32% 45.6%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $110.9M $118.7M
YoY Change
Total Liabilities & Shareholders Equity $126.4M $133.0M
YoY Change 60.68% 51.26%

Cashflow Statement

Concept 2022 Q4 2022 Q3
OPERATING ACTIVITIES
Net Income -$9.425M -$8.320M
YoY Change 3.19% -50.49%
Depreciation, Depletion And Amortization $78.00K $77.00K
YoY Change -11.36% -23.0%
Cash From Operating Activities -$6.672M -$5.878M
YoY Change -15.74% -51.82%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00
YoY Change -100.0% -100.0%
Acquisitions
YoY Change
Other Investing Activities -$52.23M -$3.384M
YoY Change -903.72% -47.92%
Cash From Investing Activities -$52.23M -$3.384M
YoY Change -904.84% -50.17%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -316.0K 75.57M
YoY Change 280.05%
NET CHANGE
Cash From Operating Activities -6.672M -5.878M
Cash From Investing Activities -52.23M -3.384M
Cash From Financing Activities -316.0K 75.57M
Net Change In Cash -59.22M 66.31M
YoY Change 4047.2% 7309.05%
FREE CASH FLOW
Cash From Operating Activities -$6.672M -$5.878M
Capital Expenditures $0.00 $0.00
Free Cash Flow -$6.672M -$5.878M
YoY Change -15.64% -50.63%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3993000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
8247000
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Central Index Key
EntityCentralIndexKey
0001374690
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36510
dei Entity Registrant Name
EntityRegistrantName
LARIMAR THERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-3857670
dei Entity Address Address Line1
EntityAddressAddressLine1
Three Bala Plaza East
CY2021Q4 us-gaap Assets Current
AssetsCurrent
72204000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
909000
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 506
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
19004
dei Entity Address City Or Town
EntityAddressCityOrTown
Bala Cynwyd
dei Entity Address State Or Province
EntityAddressStateOrProvince
PA
dei City Area Code
CityAreaCode
844
dei Local Phone Number
LocalPhoneNumber
511-9056
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
LRMR
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
43269200
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
86047000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
70097000
CY2022Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
38652000
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2428000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2107000
CY2022Q3 us-gaap Assets Current
AssetsCurrent
127127000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1049000
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2997000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3406000
CY2022Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1339000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1339000
CY2022Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
643000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
669000
CY2022Q3 us-gaap Assets
Assets
133015000
CY2021Q4 us-gaap Assets
Assets
78667000
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
849000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1660000
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7939000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6592000
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
632000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
594000
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
9420000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
8846000
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4933000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
5408000
CY2022Q3 us-gaap Liabilities
Liabilities
14353000
CY2021Q4 us-gaap Liabilities
Liabilities
14254000
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
115000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
115000000
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
43269200
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
43269200
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
17710450
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
17710450
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
43000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
18000
CY2022Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
260839000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
180645000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-142180000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-116250000
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-40000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
118662000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
64413000
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
133015000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
78667000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5582000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14028000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17032000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
32104000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2931000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2702000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9055000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9275000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
8513000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
16730000
us-gaap Operating Expenses
OperatingExpenses
26087000
us-gaap Operating Expenses
OperatingExpenses
41379000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-8513000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-16730000
us-gaap Operating Income Loss
OperatingIncomeLoss
-26087000
us-gaap Operating Income Loss
OperatingIncomeLoss
-41379000
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
193000
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-75000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
157000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-123000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-8320000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-16805000
us-gaap Net Income Loss
NetIncomeLoss
-25930000
us-gaap Net Income Loss
NetIncomeLoss
-41502000
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.37
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.37
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.92
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.92
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.32
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.32
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.48
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.48
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
22228228
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
22228228
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
18287924
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
18287924
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
19649558
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
19649558
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
16768458
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
16768458
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-8320000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-16805000
us-gaap Net Income Loss
NetIncomeLoss
-25930000
us-gaap Net Income Loss
NetIncomeLoss
-41502000
CY2022Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-17000
CY2021Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
1000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
40000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
1000
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
17000
CY2021Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-1000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-40000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-1000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-8303000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-16806000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-25970000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-41503000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
64413000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1635000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-8943000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
57105000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1675000
CY2022Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
57000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-8667000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
50056000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1666000
CY2022Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
75243000
CY2022Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-17000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
61626000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-8320000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
118662000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
89692000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1180000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-12088000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
78784000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1350000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-12609000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
67525000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1463000
CY2021Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
19885000
CY2021Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
1000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-16805000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
72067000
us-gaap Profit Loss
ProfitLoss
-25930000
us-gaap Profit Loss
ProfitLoss
-41502000
us-gaap Share Based Compensation
ShareBasedCompensation
4976000
us-gaap Share Based Compensation
ShareBasedCompensation
3993000
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
1000
us-gaap Depreciation
Depreciation
240000
us-gaap Depreciation
Depreciation
238000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
-66000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
-12000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
321000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2085000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-891000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-877000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1097000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2123000
lrmr Increase Decrease In Right Of Use Assets
IncreaseDecreaseInRightOfUseAssets
-409000
lrmr Increase Decrease In Right Of Use Assets
IncreaseDecreaseInRightOfUseAssets
-396000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-437000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-378000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-26000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
252000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-20897000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-34187000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
100000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
324000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
23000000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
26250000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-38726000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
17679000
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
75573000
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
19885000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
75573000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
19885000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
15950000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
3377000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
71436000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
69487000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
87386000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
72864000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
9000
lrmr Issuance Costs Included In Accounts Payable And Accrued Expenses
IssuanceCostsIncludedInAccountsPayableAndAccruedExpenses
330000
us-gaap Net Income Loss
NetIncomeLoss
-25900000
us-gaap Net Income Loss
NetIncomeLoss
-41500000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-142200000
CY2022Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
124700000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the accrual of research and development expense, the recording as prepaid expense of payments made in advance of the actual provision of goods or services, valuation of stock-based awards and valuation of leases. Due to inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates. On an ongoing basis, the Company evaluates its estimates and assumptions.</span></p>
CY2022Q3 lrmr Common Shares Attributable To Prefunded Warrants
CommonSharesAttributableToPrefundedWarrants
628403
CY2021Q3 lrmr Common Shares Attributable To Prefunded Warrants
CommonSharesAttributableToPrefundedWarrants
628403
CY2022Q3 lrmr Unfunded Exercise Price Of Prefunded Warrants
UnfundedExercisePriceOfPrefundedWarrants
0.01
CY2021Q3 lrmr Unfunded Exercise Price Of Prefunded Warrants
UnfundedExercisePriceOfPrefundedWarrants
0.01
CY2022Q3 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
84034000
CY2022Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
38652000
CY2022Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
122686000
CY2021Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
14905000
CY2022Q3 us-gaap Interest Receivable
InterestReceivable
200000
CY2021Q4 us-gaap Interest Receivable
InterestReceivable
0
CY2022Q3 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0
CY2021Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0
CY2022Q3 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2021Q3 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2021Q4 us-gaap Marketable Securities
MarketableSecurities
0
CY2022Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
38692000
CY2022Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
2000
CY2022Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
42000
CY2022Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
38652000
CY2022Q3 lrmr Prepaid Research And Development Expenses
PrepaidResearchAndDevelopmentExpenses
995000
CY2021Q4 lrmr Prepaid Research And Development Expenses
PrepaidResearchAndDevelopmentExpenses
676000
CY2022Q3 us-gaap Prepaid Insurance
PrepaidInsurance
957000
CY2021Q4 us-gaap Prepaid Insurance
PrepaidInsurance
944000
CY2022Q3 lrmr Payroll Taxes Receivable
PayrollTaxesReceivable
114000
CY2021Q4 lrmr Payroll Taxes Receivable
PayrollTaxesReceivable
208000
CY2022Q3 lrmr Other Prepaid Expense And Other Current Assets
OtherPrepaidExpenseAndOtherCurrentAssets
362000
CY2021Q4 lrmr Other Prepaid Expense And Other Current Assets
OtherPrepaidExpenseAndOtherCurrentAssets
279000
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2428000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2107000
CY2022Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1745000
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
43269200
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1645000
CY2022Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
836000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
596000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
909000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1049000
CY2022Q3 lrmr Depreciation Expense Excluding Leased Assets
DepreciationExpenseExcludingLeasedAssets
100000
lrmr Depreciation Expense Excluding Leased Assets
DepreciationExpenseExcludingLeasedAssets
200000
CY2021Q3 lrmr Depreciation Expense Excluding Leased Assets
DepreciationExpenseExcludingLeasedAssets
100000
lrmr Depreciation Expense Excluding Leased Assets
DepreciationExpenseExcludingLeasedAssets
200000
CY2022Q3 lrmr Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
5726000
CY2021Q4 lrmr Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
5042000
CY2022Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1433000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1098000
CY2022Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
780000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
452000
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7939000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6592000
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
115000000
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
43269200
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
us-gaap Common Stock Voting Rights
CommonStockVotingRights
Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company’s stockholders
CY2022Q3 us-gaap Dividends Payable Current And Noncurrent
DividendsPayableCurrentAndNoncurrent
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0213
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0089
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y2M15D
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y2M8D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.89
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.91
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2523305
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
18.88
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y7M6D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
868450
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
6.99
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
254979
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
59.60
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3136776
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
12.27
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y1M6D
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
100
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1329897
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
14.81
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y2M12D
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
3136776
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
12.27
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y1M6D
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
100
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1667000
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1463000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4976000
CY2022Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
14000000.0
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y4M9D
CY2022Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
100000
us-gaap Operating Lease Expense
OperatingLeaseExpense
200000
CY2021Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
100000
us-gaap Operating Lease Expense
OperatingLeaseExpense
200000
CY2022Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P7Y
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P7Y7M6D
CY2022Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.110
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.110
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
302000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1146000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1065000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1083000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1101000
CY2022Q3 lrmr Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
3213000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
7910000
CY2022Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
2345000
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
5565000

Files In Submission

Name View Source Status
lrmr-20220930_lab.xml Edgar Link unprocessable
0000950170-22-024223-index-headers.html Edgar Link pending
0000950170-22-024223-index.html Edgar Link pending
0000950170-22-024223.txt Edgar Link pending
0000950170-22-024223-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
lrmr-20220930.htm Edgar Link pending
lrmr-20220930.xsd Edgar Link pending
lrmr-ex31_1.htm Edgar Link pending
lrmr-ex31_2.htm Edgar Link pending
lrmr-ex32_1.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
lrmr-20220930_def.xml Edgar Link unprocessable
lrmr-20220930_pre.xml Edgar Link unprocessable
lrmr-20220930_htm.xml Edgar Link completed
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
lrmr-20220930_cal.xml Edgar Link unprocessable